Beryl Drugs Limited (BERLDRG.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-329.6%

-₹57.39

vs ₹24.99 price

Levered DCF

-₹26.51

After debt service

Piotroski score

5 / 9

Average

Altman Z-score

3.87

Safe zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	22.95×	19.06×	20.2×	8.05×	-8.04×	14.06×	38.62×	7.54×
P/B	0.99×	1.17×	1.74×	0.76×	0.73×	0.42×	0.24×	0.59×
P/S	0.5×	0.49×	0.59×	0.23×	0.37×	0.24×	0.15×	0.35×
EV / EBITDA	4.91×	5.45×	7.66×	4.67×	18.01×	3.84×	7.19×	5.99×
Gross margin	28.6%	36.9%	32.8%	19.7%	27.8%	31.7%	31.5%	30.2%
Operating margin	4.8%	32.9%	4.5%	4.4%	-4.5%	1.4%	2.2%	5.7%
Net margin	2.2%	2.6%	2.9%	2.9%	-4.6%	1.7%	0.4%	4.7%
Current ratio	1.52×	2.1×	1.78×	1.63×	1.24×	1.24×	1.13×	0.98×
Debt / equity	0.25×	0.43×	0.57×	0.56×	0.73×	0.65×	0.69×	0.43×
Interest coverage	2.71×	14.02×	2.54×	2.64×	-1.5×	0.43×	0.85×	4.97×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	4.3%	6.1%	8.6%	9.5%	-9.0%	3.0%	0.6%	7.8%
Return on invested capital	5.2%	35.5%	6.2%	6.9%	-3.5%	1.0%	0.6%	4.9%
Return on assets	2.8%	3.6%	4.4%	4.4%	-3.7%	1.3%	0.3%	4.1%
Free cash flow yield	-5.3%	-0.7%	-3.4%	14.9%	-16.7%	-21.3%	-91.3%	-65.5%
Earnings yield	4.4%	5.2%	5.0%	12.4%	-12.4%	7.1%	2.6%	13.3%
Enterprise value	₹119.2M	₹144M	₹204.9M	₹104.3M	₹103.2M	₹80.2M	₹66.9M	₹75.8M
Net debt / EBITDA	0.89×	1.23×	1.86×	1.91×	8.76×	2.24×	5.2×	2.48×
Cash conversion cycle (days)	84	108	101	58	149	168	100	79